New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For MLNX;ISIS;INVN;TPX;CRUS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 26, 2014
10:07 EDTTPXHigh option volume stocks
Subscribe for More Information
November 25, 2014
13:03 EDTINVNInvenSense continues to have downside risk, says Pacific Crest
Pacific Crest said InvenSense assumes 100% market share for their motion sensors in both the iPhone and Samsung phones to make guidance, but both STMicroelectronics and Bosch are gaining share at both companies. The analyst expects earnings to get squeezed from market share losses and further margin pressure. Shares are Sector Perform rated.
07:49 EDTTPXTempur Sealy share gains likely to continue, says BofA/Merrill
BofA/Merrill said Tempur's North American sales have been impressive and gained share in Q3. The firm expects Tumpur to report earnings growth above the industry for the next two years and sees further upside from greater-than-expected Sealy synergies and debt pay down. Shares are Buy rated with a $61 price target.
07:09 EDTISISIsis Pharmaceuticals initiates pivotal Phase 3 study evaluating ISIS-SMN
Subscribe for More Information
November 24, 2014
08:36 EDTMLNXMellanox selected by Center for Biological and Sequence Analysis for InfiniBand
Mellanox announced the Center for Biological and Sequence Analysis at the Risø Campus of Denmark Technical University has selected Mellanox’s end-to-end FDR 56Gb/s InfiniBand solution for the center’s new supercomputer, making Denmark a global leader in bioinformatics.
November 20, 2014
07:24 EDTISIS, INVNGoldman to hold a conference
Subscribe for More Information
06:40 EDTISISIsis Pharmaceuticals price target raised to $62 from $53 at Piper Jaffray
Subscribe for More Information
November 18, 2014
15:48 EDTISISGenzyme, Isis present KYNAMRO data at AHA meeting
Genzyme, a Sanofi (SNY) company, and Isis Pharmaceuticals (ISIS) announced that new two-year data from a phase 3 long-term extension study of KYNAMRO injection was presented at a scientific session at the annual American Heart Association meeting. In the study, a retrospective analysis showed that patients treated with KYNAMRO for a mean of two years had a significant reduction in Major Adverse Cardiovascular Events compared to two years prior to therapy. The rate of MACE in patients treated with KYNAMRO for two years were adjudicated by an independent committee and compared to the rate of MACE in the same patients based on their medical history prior to treatment with KYNAMRO. In this analysis, MACE were identified in 62% of patients during two years prior to KYNAMRO treatment, and 9% of patients during a mean of 24.4 months after initiation of treatment with KYNAMRO.
November 17, 2014
16:43 EDTTPXTempur Sealy appoints Jay Spenchian as Chief Marketing Officer
Subscribe for More Information
07:56 EDTMLNXMellanox wins two of three DOE projects, says Jefferies
Subscribe for More Information
07:52 EDTMLNXDepartment of Energy awards $425M for supercomputing technologies
Subscribe for More Information
November 14, 2014
16:52 EDTTPXGreenlight Capital gives quarterly update on stakes
Subscribe for More Information
15:41 EDTISISIsis Pharmaceuticals management to meet with Piper Jaffray
Meeting to be held in Kansas City, MO on November 18 hosted by Piper Jaffray.
November 13, 2014
14:47 EDTINVNInvenSense management to meet with Craig-Hallum
Subscribe for More Information
10:01 EDTINVNOn The Fly: Analyst Initiation Summary
Subscribe for More Information
05:44 EDTINVNInvenSense initiated with an Outperform at JMP Securities
Subscribe for More Information
05:34 EDTISISAstraZeneca, Isis Pharmaceuticals to co-develop oligonucleotide delivery methods
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use